Covid-19 popup
A message from Novartis on COVID-19
For additional support, including samples, please
contact your Novartis representative
LEARN MORE >
Covid-19 popup
COVID-19 update
Covid-19 popup
Covid-19 popup
Covid-19 popup
A message from Novartis on COVID-19
For additional support, including samples, please
contact your Novartis representative
LEARN MORE >
Covid-19 popup
COVID-19 update
Group of patients with plaque psoriasis being treated with COSENTYX
START HERE to see
what COSENTYX® can
do for your patients
DERMATOLOGY RHEUMATOLOGY OFFICE SUPPORT
 
 
Reference: 1. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777-783.
 
Click or scroll down to see full Indications and Important Safety Information
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
COSENTYX® (secukinumab) is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients in COSENTYX. Cases of anaphylaxis have been reported during treatment with COSENTYX.
Scroll down to read more
For US Healthcare Professionals Only
Please rotate your device for the best mobile experience.